Sources: EMBRAZE Phase 2 press release Scholar Rock, June 2025 EMBRAZE full publication Nature Medicine, 2026 BELIEVE trial: bimagrumab + semaglutide HCPLive, May 2026 Lilly pauses bimagrumab trial BioPharma Dive, Sept
P., de Azevedo, M
First-time patients save 10% on any single session, and series pricing brings down the per session cost
At the 3-month timepoint, however, the symptomatic and OI groups differed in tCho levels and 3-month tCho levels were associated with somatic symptoms at 3 months
Early Phase Possible appetite or fullness changes Digestive adjustment Possible nausea or bloating Response varies by dose and individual tolerance First Few Weeks Some patients may notice appetite changes Eating patterns may begin to shift Energy and blood sugar response may vary Digestive adjustment may continue Provider follow-up helps guide next steps Ongoing Early Treatment Some patients may begin noticing weight-related changes Portion sizes may change Appetite patterns may continue adjusting Side effects may improve or require provider guidance Progress depends on the individual treatment plan Continued Provider Monitoring Provider reviews response and tolerance Weight-related progress may vary Appetite patterns may continue changing Lifestyle habits may support progress Dose or care plan may be adjusted if appropriate Longer-Term Follow-Up Ongoing progress varies by patient Provider may review labs, tolerance, and treatment response Lifestyle habits may support long-term weight management Treatment may continue, change, or stop based on clinical review What Affects How Fast You See Results
PLoS One 5:e9505
